Abstract-Two active metabolites of the angiotensin type 1 (AT 1 ) receptor blocker losartan have been described previously, EXP3174 and EXP3179. Whereas EXP3174 is the main antihypertensive AT 1 receptor-blocking metabolite, the role of EXP3179 is widely unknown. Recently, a subgroup of AT 1 receptor blockers has been identified as ligands for the peroxisome proliferator-activated receptor ␥ (PPAR-␥). Here we characterize the PPAR-␥-activating properties of the 2 active losartan metabolites. PPAR-␥ activity was measured with a chimeric Gal4-DNA-binding domainhPPAR␥-ligand-binding domain (LBD) fusion protein on a Gal4-dependent luciferase reporter system. EXP3179 prominently induced the activation of the PPAR-␥-LBD reaching a maximum at 100 mol/L with a 7.1Ϯ1-fold induction (PϽ0.05 versus vehicle-treated cells We and others recently demonstrated that a subset of ARBs, including losartan, induces the activity of a nuclear hormone receptor named peroxisome proliferator-activated receptor ␥ (PPAR-␥) by partial agonism. 2,3 The direct activation of the ligand-binding domain of PPAR-␥ by ARBs is independent of their angiotensin type 1 receptor (AT 1 R) blocking actions. 3 PPAR-␥ functions as a transcriptional regulator in adipose tissue where it regulates multiple genes involved in lipid and glucose metabolism. 4 Activated by synthetic full agonists like thiazolidinediones/glitazones, PPAR-␥ markedly improves whole-body insulin sensitivity resulting in decreased levels of fasting plasma glucose, fasting plasma insulin, and plasma triglycerides. 5 Thus, PPAR-␥ activation by ARBs presents a promising molecular mechanism for metabolic actions of these compounds.
T he Losartan Intervention For End point reduction in hypertension (LIFE) study has shown that hypertensive patients receiving the angiotensin type 1 receptor blocker (ARB) losartan have a 25% lower rate of new-onset diabetes than patients treated with the ␤-blocker atenolol. 1 Although these data suggest a possible antidiabetic action of losartan, the molecular mechanisms are widely unknown.
We and others recently demonstrated that a subset of ARBs, including losartan, induces the activity of a nuclear hormone receptor named peroxisome proliferator-activated receptor ␥ (PPAR-␥) by partial agonism. 2, 3 The direct activation of the ligand-binding domain of PPAR-␥ by ARBs is independent of their angiotensin type 1 receptor (AT 1 R) blocking actions. 3 PPAR-␥ functions as a transcriptional regulator in adipose tissue where it regulates multiple genes involved in lipid and glucose metabolism. 4 Activated by synthetic full agonists like thiazolidinediones/glitazones, PPAR-␥ markedly improves whole-body insulin sensitivity resulting in decreased levels of fasting plasma glucose, fasting plasma insulin, and plasma triglycerides. 5 Thus, PPAR-␥ activation by ARBs presents a promising molecular mechanism for metabolic actions of these compounds.
Losartan induced PPAR-␥ activity only at high concentrations in vitro. 3 Losartan is hepatically metabolized by the cytochrome-P450 pathway and exerts its antihypertensive actions in vivo predominantly by its main metabolite, EXP3174 ( Figure 1 ). 6, 7 During hepatic metabolization of losartan, additional active metabolites are produced, including EXP3179 (Figure 1 ). This metabolite has a significant molecular homology with indomethacin, an antiinflammatory cyclooxygenase (COX) inhibitor, and mediates a variety of AT 1 R-independent, pleiotropic functions (eg, inhibition of platelet aggregation, endothelial adhesion molecule expression, etc). 7 Indomethacin has been also identified as an activator of PPAR-␥. 8 Given the structural homology of indomethacin and EXP3179, it is likely that EXP3179 has 1 also PPAR-␥-binding properties. We hypothesized that the PPAR-␥-activating properties of losartan in vivo might be enhanced by its active metabolites and that PPAR-␥ activation by losartan metabolites may provide a potential mechanism of the antidiabetic actions of losartan observed in clinical trials.
Methods

Cell Culture
3T3-L1 adipocytes were differentiated as described previously in the absence of 3-isobutyl-1-methylxanthine. 3 After 9 days, Oil-Red-O staining was performed to assess lipid accumulation. COS-7 cells were purchased from American Type Culture Collection.
Synthesis of EXP3179
The in vitro synthesis of EXP3179 has been described previously. 7 In brief, EXP3179 was synthesized from losartan by incubation with RuCl 3 and H 2 O 2 in MeCN followed by liquid chromatography purification.
Transfection and Luciferase Assay
Transient transfection and luciferase assays were performed as described previously. 3 COS-7 cells were transfected using Lipofectamine 2000 (Invitrogen) with pGal4-human [h] PPAR␥DEF (hPPAR-␥ ligand-binding domain [LBD] fused to Gal4 DBD) and pGal5-TK-pGL3 kindly provided by Bart Staels (UR 545 INSERM), and 10 ng pRL-CMV, a renilla luciferase control reporter vector. After 4 hours, transfection medium was replaced by 10% FBS DMEM plus the indicated compounds or vehicle (dimethylsulfoxide), and luciferase activity was measured after 24 hours.
Quantitative Real-Time PCR
Real-time PCR was performed as described previously with an ABI 7000 sequence detection system. 3 Day-8 adipocytes were serum starved overnight, incubated with compounds for 24 hours, and RNA was isolated. Mouse 18S ribosomal RNA was chosen as endogenous controls (housekeeping genes).
Statistical Analysis
ANOVA and t test were performed for statistical analysis as appropriate. Statistical significance was designated at PϽ0.05. Values are expressed as meanϮSD.
Results
EXP3179 Enhances 3T3-L1 Adipocyte Differentiation
To examine whether losartan metabolites regulate a PPAR-␥-mediated cell function, differentiation of 3T3-L1 adipocytes was studied in the presence and absence of losartan, EXP3174, EXP3179, and pioglitazone. EXP3179 (10 mol/L) potently promoted 3T3-L1 adipocyte differentiation as indicated by an increased lipid accumulation assessed with Oil-Red-O staining (Figure 2A and 2B) . In similar concentrations, losartan (10 mol/L) weakly induced lipid accumulation, and the losartan metabolite EXP3174 had no effect (Figure 2A and 2B). Concentration-response experiments revealed that EXP3179-mediated 3T3-L1 adipocyte differentiation started between 1 and 10 mol/L ( Figure 2B ). Losartan markedly enhanced the differentiation process only at high concentrations (100 mol/L; Figure 2B ).
EXP3179 Induces PPAR-␥ Target Gene Expression
Consistent with the stimulation of adipocyte differentiation, EXP3179 (10 mol/L) induced mRNA expression of the adipogenic marker and PPAR-␥ target gene, adipose protein 2, in 3T3-L1 adipocytes ( Figure 3A ). Losartan and EXP3174 at 10-mol/L concentrations had no effect on adipose protein 2 mRNA expression.
A specific characteristic of agonists for PPAR-␥ is the downregulation of the receptor on mRNA and/or the protein 9 To additionally characterize EXP3179 as a PPAR-␥ activator, we studied the regulation of PPAR-␥2 mRNA expression in 3T3-L1 adipocytes under stimulation with losartan metabolites. In line with pioglitazone-mediated PPAR-␥ downregulation, EXP3179 significantly downregulated PPAR-␥2 mRNA expression in 3T3-L1 adipocytes, whereas losartan and EXP3174 had no effect ( Figure 3B ).
EXP3179 Activates the PPAR-␥ Ligand-Binding Domain
To prove that EXP3179 activates PPAR-␥, we assessed its ability to directly activate the PPAR-␥ LBD by using a chimeric Gal4-DBD-hPPAR␥-LBD fusion protein on a Gal4-dependent luciferase reporter. EXP3179 prominently induced the activation of the PPAR-␥ LBD reaching a maximum at 100 mol/L with a 7.1Ϯ1-fold induction (PϽ0.05 versus vehicle-treated cells; Figure 4 ). Maximum PPAR-␥ LBD activation by EXP3179 reached 51% of the maximum response induced by the full PPAR-␥ agonist pioglitazone, identifying EXP3179 as a partial PPAR-␥ agonist ( Figure 4 ). EXP3174 did not induce PPAR-␥ LBD activation ( Figure 4 
Discussion
This study identifies the active losartan metabolite EXP3179 as a partial PPAR-␥ agonist. EXP3179 markedly promotes 3T3-L1 adipocyte differentiation, induces PPAR-␥ target gene expression, and directly activates the PPAR-␥ LBD. PPAR-␥ activation by EXP3179 may provide a mechanism for the beneficial antidiabetic actions of losartan observed in clinical trials. Losartan is a prodrug that is actively metabolized by the cytochrome P450 isoenzyme CYP2C9 on first liver passage to its main antihypertensive metabolite, EXP3174. 6 EXP3174 is 10-fold to 40-fold more potent compared with losartan and mediates most of the AT 1 R-blocking effects of losartan. 6 Recently, an important intermediate aldehyde metabolite of losartan, EXP3179, has been identified. In contrast to EXP3174, EXP3179 has very little AT 1 R-blocking activity and has been hypothesized to mediate pleiotropic actions of losartan observed in clinical and animal studies. 6 Kramer et al 7 demonstrated that EXP3179 potently inhibits the expression of endothelial COX-2, thereby exerting potent antiinflammatory actions. In addition, Watanabe et al 10 showed that EXP3179 stimulates endothelial NO synthase phosphorylation and suppresses endothelial cell apoptosis induced by tumor necrosis factor ␣ independent of AT 1 R-mediated signaling. The molecular mechanism underlying these pleiotropic EXP3179 actions are unknown. Ligand-activated PPAR-␥ exerts potent antiinflammatory actions by inhibiting the action of proinflammatory transcription factors, such as AP-1 and nuclear factor B. 11 Activation of PPAR-␥ has also been shown to repress COX-2 promoter activity and mRNA expression by interacting with the c-jun component of the AP-1 complex. 12 EXP3179-mediated activation of PPAR-␥ may, therefore, provide a new mechanism of the observed antiinflammatory actions of this compound.
EXP3179 induced PPAR-␥ activation as a partial agonist, which implies the consideration of whether the compound may antagonize the actions of a full glitazone agonist during . EXP3179 activates the PPAR-␥ LBD. COS-7 cells were transiently transfected with the pGal4-hPPAR␥DEF and pGal5-Tk-pGL3 reporter followed by stimulation with the indicated compounds. Firefly luciferase activity was measured after 24 hours and normalized with activity of cotransfected renilla luciferase. Experiments were repeated 3 times, and results are presented as meanϮSD. 1, 14, 15 The molecular mechanism of these metabolic actions is still far from being understood. It is now well known that blockade of AT 1 R results in multiple beneficial effects on insulin and glucose metabolism mediated via an improvement of muscular and pancreatic blood flow or an inhibition of deleterious angiotensin II actions on insulin signaling. 14 We and others recently demonstrated that certain ARBs act like activators of PPAR-␥, which might contribute to their antidiabetic effects. 2, 3 However, because PPAR-␥ activation by losartan was only achieved at very high concentrations, it appears unlikely that PPAR-␥ is responsible for the antidiabetic actions of this compound. 3 In contrast, the losartan metabolite EXP3179 induced PPAR-␥ activation more potently compared with losartan identifying this metabolite as a possible mediator of the antidiabetic properties of losartan.
Schupp et al PPAR-␥ and Losartan Metabolites
The question remains as to whether EXP3179-mediated PPAR-␥ activation plays a role in the antidiabetic actions of losartan observed in clinical studies. Kramer et al 7 reported that after a single oral dose of losartan (100 mg), maximum serum concentrations of EXP3179 between 0.1 and 1 mol/L were achieved. In the present study, PPAR-␥-mediated adipocyte differentiation, as well as activation of the PPAR-␥ LBD by EXP3179, started between 1 and 10 mol/L. In consideration of the high lipophilicity of EXP3179 rendering it receptive for tissue accumulation and in consideration of an additional increase of serum levels under chronic losartan treatment, EXP3179 concentrations required for PPAR-␥ activation may well be reached under losartan treatment. However, rapid hepatic metabolization of EXP3179 has to be taken into account, and additional studies are required to assess whether stable serum and tissue concentrations of EXP3179 are achieved to activate PPAR-␥ in patients treated with different doses of losartan.
Perspectives
PPAR-␥ activation by EXP3179 may provide a new mechanism of antidiabetic actions induced by losartan. In addition, the identification of an additional PPAR-␥-activating compound with a chemical structure equal to ARBs helps us to understand the characteristic of such substances and supports the development of new dual ARB/PPAR-␥ ligands for the treatment of patients experiencing hypertension, insulin resistance, or diabetes. 
EXP3179 Inhibits
Introduction
Occlusive arterial thrombosis following atherosclerotic plaque rupture represents the major pathophysiological mechanism underlying acute coronary syndromes (ACS) or cerebrovascular events, i.e. stroke. 1 Atherosclerotic plaque rupture injures the integrity of the vascular wall and leads to exposure of highly pro-coagulatory extracellular matrix (ECM) components. 2, 3 These include collagen-I, a major element of the structurally altered ECM in atherosclerotic vessels. [4] [5] [6] The importance of collagen-platelet interactions via the platelet collagen receptor glycoprotein (GP)VI for arterial thrombus formation following vessel injury has recently been recognized by experimental and clinical data. In this regard, GPVI seems to be crucial for thrombus formation in response to platelet contact with human atherosclerotic plaque material ex vivo and in vivo at sites of murine arterial vascular injury. 7, 8, 9 Subsequently, platelet GPVI-receptor surface expression was found to be elevated in patients with ACS. 10 Thus, blockade of GPVI-receptor activation may represent a novel pharmacological target to inhibit atherothrombotic events following atherosclerotic plaque rupture. EXP3179 was originally identified as an active metabolite of the angiotensin II type 1 (AT 1 )-receptor antagonist Losartan (LOS), which is produced during the hepatic metabolization of LOS by the cytochrome-P450 pathway (figure 1A).
We recently reported that EXP3179 is detectable in patients after LOS administration and inhibits platelet activation, even though the underlying mechanisms remained unclear. 11 Current observations from other groups revealed, that EXP3179 activates the endothelial nitric oxide synthase (eNOS) and acts as a peroxisome proliferator-activated receptor (PPAR)-gamma agonist. [11] [12] [13] So far, the potentially beneficial effects of EXP3179 have only been investigated in concomitance and dependence of LOS treatment. In contrast, we here postulated that EXP3179 might possess an individual pharmacological potential independent of LOS application and its impact on the AT 1 -receptor. Therefore, we analysed the effects of EXP3179, LOS and EXP3174 -the main metabolite of LOS and specific AT 1 -receptor antagonist -on collagen-I and GPVI-receptor-dependent platelet activation, adhesion and aggregation and evaluated the impact of EXP3179 on acute platelet adhesion to the injured arterial vessel wall in vivo.
Materials and Methods
Synthesis of EXP3179
The 1 H-and 13 CNMR spectra were recorded on a Bruker AC 300 spectrometer at 300 (75). Chemical shifts are reported as % values (ppm) downfield from Me 4 Si. Mass spectrometry was performed on a Bruker-Franzen Esquire LC mass spectrometer. Flash column chromatography was carried out using Merck silica gel 60 (40-63 and 15-40 m) and 60G (5-40 m). Thin-layer chromatography (TLC) was carried out using aluminum sheets precoated with silica gel 60 F 254 (0.2 mm; Merck, Germany). Chromatographic spots were visualized by UV and/or spraying with an acidic, ethanolic solution of p-anisaldehyde or an ethanolic solution of ninhydrin followed by heating. IBX (2-iodoxybenzoic acid). All commercial chemicals were used without further purification. EXP3179 was synthesized by a modified protocol, which provides higher yields than the previously reported methods.
11,13 Losartan (0.422 g, 1 mmol) was oxidized with IBX (2-iodoxybenzoic acid, 0.321 g, 1.2 mmol) in DMSO (5 mL) at room temperature for 6 h. CH 2 Cl 2 (30 mL) was added and the solution was washed with water (3 x 30mL), NaHCO 3 solution (3 x 30 mL, sat.), and brine (1 x 30 mL). The solvent was removed after drying (Na 2 SO 4 ) in vacuo to yield the product (410 mg, 98%) EXP3179.
Synthesis of EXP3174 via EXP3179
A mixture of 0.147 g (0.35 mmol) of EXP3179 and 0.287 g (3.3 mmol) of activated manganese dioxide in 2 ml of H 2 O was refluxed for 78 hrs. 
Blood Samples
Human peripheral venous blood samples were taken with a loose tourniquet to avoid artefacts through a short venous catheter inserted into the forearm of healthy volunteer donors, who had not taken any medication known to interfere with platelet activation for at least 14 days.
Aggregometric Analysis
Platelet aggregation was evaluated by optical aggregometry as described previously. 16 After adjustment to a total platelet count of 2x10 8 /mL, Platelet-rich plasma (PRP) was incubated with varying doses of EXP3179, LOS, EXP3174 or the corresponding solvents for 15 min. Collagen (type)-I (Probe&Go, Germany) or 4C9 (provided by the GSF-research centre for Environment and Health GmbH, Institute for molecular Immunology, Munich, Germany), a monoclonal GPVI-receptor stimulating antibody were added in varying concentrations to induce platelet activation. As reported previously, 4C9 detects the GPVI-receptor on the platelet surface. 3 In addition, adenosin-5`-diphosphate (ADP, 5 μmol/L; Probe&Go, Germany) or thrombin-receptor-activating-peptide (TRAP) (25 μmol/L; SigmaAldrich, USA) were used to induce platelet activation. To evaluate the impact of EXP3179 on atherosclerotic plaque material-induced platelet aggregation, we followed a protocol recently published by Penz et al. 9 Patient consent was obtained as approved by the Institutional Ethics Committee. For experiments with murine PRP, samples were pooled. Maximal aggregation at 5 min was used as measurement of aggregation.
Flow Cytometry
Evaluation of the surface expression of platelet membrane glycoproteins was performed by immunolabeling followed by flow cytometry analysis as described previously. 17 In brief, PRP (adjusted to 2x10 8 platelets/mL) was incubated with varying doses of EXP3179, LOS, EXP3174 or the corresponding solvents for 30 min. followed by incubation with varying dosages of 4c9 or collagen-I and PAC-1 antibody, an epitope of the activated fibrinogen receptor complex (anti-PAC-1 FITC, Becton Dickinson, USA) for 30 min. Samples were fixated with 0.5% paraformaldehyde and analysed within 2 hours. 10,000 events were analysed. Specific antibody binding was expressed as mean intensity of immunofluorescence.
Flow Chamber
ACD (acid citrate dextrose)-anticoagulated whole blood samples were obtained as described previously. 7 Coverslips were coated with collagen-I (20 g/mL). Platelets were perfused through a flow chamber (Oligene, Germany) mounted on the stage of an Axiovert 100 (Zeiss, Jena, Germany) microscope at high shear rate (1000 sec -1 ). 18 Images were taken randomly and evaluated offline using a computer-assisted image analysis program (Cap Image 7.1; Zeintl, Germany). The duration of one set of experiments was limited to one hour in order to preserve platelet reactivity. To investigate the impact of EXP3179, LOS and EXP3174 on GPVI-receptor mediated cell adhesion on collagen-I under shear conditions, the Flp-In TM system (Invitrogen, Carlsbad, USA) was used as described elsewhere. 7 In short, the Flp-In TM system was used to generate a CHO-cell line stably expressing the human GPVI-receptor. Non-transfected Flp-In TM -CHO-cells served as controls. CHO-GPVI and CHO-cells were cultured using HAM´s F12 containing 10% FCS + 1% penicillin/streptomycin. For culturing the CHO-GPVI cell line 400 g/mL hygromycin were added. Surface expression of the human GPVI-receptor by CHO-cells was tested by flow cytometry using the anti-GPVI monoclonal antibody 5C4 (see supplementary data, figure 3 ). Both cell lines were perfused over collagen-I (20 g/mL) or bovine serum albumin (BSA, 3%) coated glass coverslips in a cell concentration of 500,000/mL at a constant shear rate (1000 sec -1 ). Experiments were recorded in real time and evaluated off-line using Cap Image software (Cap Image 7.1; Zeintl, Germany).
Intravital Fluorescence Microscopy
For intravital fluorescence microscopy (IVM) of the injured carotid artery, 12 weeks old C57BL6/J mice (Charles River; Sulzfeld, Germany) were anaesthetized by intraperitoneal injection of Midazolam (5 mg/kg bodyweight), Medetomidine (0.5 mg/kg bodyweight) and Fentanyl (0.05 mg/kg bodyweight). Murine platelets were isolated from whole blood samples and labelled with 5 -(and -6)-carboxyfluorescein diacetate, succimidyl ester (DCF). The final platelet concentration was 2x10 8 in 500μL PRP. After pre-incubation of murine platelets with either EXP3179 or the diluent (15 min), samples were administered via a jugular catheter. Adhesion of fluorescent platelets was analysed by in situ video microscopy before and after carotid injury caused by ligature of the common carotid artery for 5 min as described previously. 3 Adherent platelets were measured using a computer-assisted programme and are given per mm 2 (Capimage, Zeintl, Germany). All experiments were approved by the Institutional Animal Care and Use committee.
Statistics
Data are given as mean SD of at least 3 independent experiments. Student`s t-test was used. Data are given as mean SD. A p-value <0.05 was considered statistically significant. Statistical analysis was performed using SPSS.
Results
EXP3179 and LOS Dose-Dependently Inhibit Collagen-I Induced Aggregation and Activation of Human Platelets
After incubation of PRP with increasing dosages of EXP3179, LOS, EXP3174 or the appropriate solvent platelet aggregation was induced by stimulation with varying collagen-I concentrations and analysed by optical aggregometry. EXP3179 and LOS similarly and dose-dependently inhibited collagen-I-induced aggregation of human platelets, reaching significant effects at a concentration of 500 M after stimulation of PRP with 1 g/mL and 2 g/mL collagen-I (EXP3179 10 6.2%, LOS 20 9%, each vs PRP 63 9%, p<0.01, n=3-6, Figure 1B ). In contrast, EXP3174 did not influence collagen-I dependent platelet aggregation. While LOS has already been reported to inhibit ADP or TRAP-dependent platelet aggregation, we did not find any impact on these parameters after pre-incubation of PRP with EXP3179 ( Figure 1C Platelet activation leads to a rapid conformational change of the GPIIb-IIIa receptor complex enabling soluble plasmatic fibrinogen binding, which is considered as a major step towards platelet aggregation. 19 The impact of EXP3179 on GPIIb-IIIa activation was evaluated by flow cytometry using the conformation-dependent antibody PAC-1, an epitope of the activated fibrinogen receptor complex. 16 Platelets were pre-incubated with increasing dosages of EXP3179, LOS, EXP3174 or the indicated solvent followed by incubation with varying concentrations of collagen-I (for dose-response experiments see supplementary data, figure 1). EXP3179, LOS and -to a lesser extent EXP3174 -dose-dependently reduced the expression of PAC-1 reaching a maximum effect at a concentration of 500 M after stimulation of PRP with 5 g/ml collagen-I (EXP3179 11.5 2, p<0.01, LOS 12.9 1.8, p<0.01, EXP3174 33.75 9.9, p<0.05, each vs stimulated (stim) PRP 65.82 19.3, n=4-7, Figure 1D ). No difference between administration of solvent and PRP alone was detected (see supplementary data, figure 1). EXP3179 did not affect TRAP-or ADP -induced PAC-1 expression (data not shown).
EXP3179 Reduces Human Platelet Adhesion on Collagen-I under Shear Conditions
Platelet adhesion under dynamic shear conditions -as present in vivo-can be simulated by using a flow chamber. 20 As reported by other groups, LOS and EXP3174 may influence collagen-dependent adhesion of human platelets under flow. 21 To evaluate the impact of EXP3179 on this parameter, whole blood samples were labelled with rhodamin-6G and incubated with solvent or EXP3179. Platelet adhesion was investigated under constant perfusion over collagen-I coated cover slides. EXP3179 significantly inhibited platelet adhesion evaluated under high shear rate (1000sec -1 ) (44.7 14.4% vs. 100%; p<0.01; n=5; Figure 1E ) in comparison to solvent administration. As high shear rates are predominantly present in the arterial branches and birfurcations of the cardiovascular system and may play an important role at sites of atherosclerotic lesions, 20, 22 these results indicate an effective inhibition of platelet adhesion by EXP3179 under pathophysiological arterial flow conditions.
EXP3179 and LOS Inhibit Human GPVI-Receptor-dependent Platelet Activation and Aggregation
To further evaluate the potential mechanisms underlying the anti-aggregatory effects of EXP3179 following collagen stimulation, we analysed the impact of EXP3179, LOS and EXP3174 on the activation of the major platelet collagen receptor GPVI. Therefore, human PRP was pre-incubated with EXP3179, LOS or EXP3174 and stimulated with the selective GPVI-receptor activating antibody 4C9, which has been shown to induce platelet activation via GPVI-receptor ligation.
23 EXP3179 and LOS dose-dependently inhibited GPVI-dependent platelet aggregation reaching a maximum effect at a concentration of 500 M after stimulation of PRP with 0.1 g/mL 4c9. EXP3174 did not have any detectable influence on this parameter (EXP3179 18.8 4.9%; LOS 20 9.6%, each vs PRP 70.3 1%, each p<0.01, Figure  2A ). Furthermore, flow cytometry experiments revealed that the 4C9-dependent platelet activation represented by PAC-1 expression was substantially reduced in the presence of EXP3179 and LOS reaching a maximum effect at a concentration of 500 M after stimulation of PRP with 0.1 g/mL 4c9 (see supplementary data for dose-response experiments, figure 2) (EXP3179 25.2 5.8, LOS 33.2 9.7, each vs stim PRP 508.4 18.9, each p<0.01, Figure 2B ). EXP3174 did not significantly influence 4c9-dependent platelet activation. We did not detect any difference between administration of solvent and PRP alone (see supplementary data, figure  2 ).
EXP3179 and LOS Inhibit GPVI-Receptor Dependent Cell Adhesion on Collagen-I under Shear Conditions
To further specify the influence of EXP3179 on GPVI-receptor dependent cell adhesion under shear conditions, GPVI-receptor-expressing CHO cells were used as previously described. 
EXP3179 Decreases Human Platelet Aggregation after Stimulation with Human Atherosclerotic Plaque Material
Thrombus formation at sites of atherosclerotic lesions seems to be critically influenced by collagen-induced platelet adhesion via GPVI-receptor activation. 9 Therefore, we investigated the impact of EXP3179 on platelet aggregation in response to components of human carotid atherosclerotic plaques ex vivo by aggregometry. After incubation with solvent or EXP3179, PRP was stimulated with homogenized atherosclerotic plaque material from patients who had undergone carotid thrombendarterectomy. EXP3179 significantly inhibited platelet aggregation following stimulation with human plaque homogenates (18.7 19.8% vs 56.7 16.7%; p<0.01; n=4; Figure 4 ) compared to solvent.
EXP 3179 Reduces Murine Platelet Aggregation in vitro and Platelet Adhesion in vivo
Stable murine platelet adhesion and aggregation at sites of acute vessel injury in vivo are substantially influenced by GPVI-receptor availability.
3,7 Therefore, we evaluated the impact of EXP3179 on murine platelet aggregation and adhesion. To investigate potential species-specific differences of EXP3179, murine platelet aggregation was first investigated ex vivo. As shown for human platelets, EXP3179 significantly inhibited murine platelet aggregation after stimulation with collagen-I in comparison to PBS (data not shown) or solvent administration (25.3 24.8% vs 79.5 7.6%; p<0.01; n=8 animals, PRP was pooled for 3 experiments; Figure 5A ). To evaluate the influence of EXP3179 on murine platelet activation in vivo, a mouse model of carotid injury was used and platelet adhesion at the site of injury was visualized by intravital fluorescence microscopy, as described previously.
3 Murine DCF-labelled platelets were pre-incubated with EXP3179 or solvent and administered via a venous catheter. Carotid injury was induced by ligature of the common carotid artery as described elsewhere. 
Discussion
Here we identify EXP3179 as an individual and selective inhibitor of GPVI-receptor dependent platelet activation and aggregation in vitro and in vivo independent of AT 1 -receptor antagonism.
Acute vessel injury by atherosclerotic plaque rupture exposes pro-coagulatory elements of the subendothelial ECM to circulating platelets, which are instantly activated. Subsequently, occlusive arterial thrombosis may occur and result in ACS or stroke. 1 In this regard, collagen-I is one of the major pro-coagulant ECM components in atherosclerotic vessels, which plays a critical role for stable platelet adhesion at the site of injury. 2 The major platelet collagen receptor is considered to be GPVI as suggested by recent experimental and clinical evidence showing the importance of GPVI-receptor activation in collagen-dependent platelet adhesion and thrombus formation, both in vitro and in vivo. 3, 8, 24 Interestingly, activation of GPVI may especially be critical for thrombotic events following atherosclerotic plaque rupture. 9 Thus, inhibition of GPVI-receptor activation may represent a novel pharmacological target in the search of more selective and specific anti-thrombotic agents for the prevention and/or treatment of acute occlusive arterial thrombosis, e.g. myocardial infarction or stroke.
Blockade of the renin-angiotensin system (RAS) by AT 1 -receptor antagonists such as LOS effectively reduce the incidence of cardiovascular events as demonstrated by large scale clinical trials. 25, 26 This impact seemingly involves the generation of active metabolites, i.e. EXP3179 or EXP3174. 27, 11 Based on recent observations which revealed various potentially vasoprotective effects of EXP3179, we hypothesised, that EXP3179 might possess an individual pharmacological potency, which may not only contribute to the beneficial effects of LOS but qualify EXP3179 as an independent candidate for future treatment strategies to prevent acute atherothrombosis. Here, we demonstrate that EXP3179 selectively reduces collagen-dependent human platelet activation, adhesion and aggregation independent of AT 1 -receptor antagonism. In this regard, Kalinowski et al. already reported that application of LOS itself impairs collagen-induced platelet aggregation and adhesion, which was attributed to a release of NO. 21 Indeed, Watanabe et al. recently identified EXP3179 as a potent activator of the eNOS phosphorylation. 12 In platelets, however, the role of eNOS remains controversially discussed. Furthermore, eNOS-associated signalling involves not only collagen-related but also alternative pathways, e.g. thrombin or ADP, both of which were not seen to be influenced by EXP3179 in the present study. [28] [29] [30] Instead, we show that EXP3179 markedly inhibited GPVI-receptor-mediated platelet aggregation and activation as determined by platelet PAC-1 expression. Furthermore, EXP3179 -in contrast to the main LOS metabolite EXP3174 -substantially reduced the adhesion of GPVIreceptor expressing CHO-cells on collagen-I under shear conditions confirming the specific impact of EXP3179 on GPVI-receptor function. Although the relevance of GPVI-receptor activation in experimental murine arterial thrombosis has lately been critically discussed, 31 recent observations by Penz et al. again emphasized the importance of collagen-dependent platelet activation via the GPVI-receptor for acute thrombus formation at sites of human atherosclerotic lesions. 9 Therefore, we here investigated -in addition to the in vitro experiments -the direct impact of EXP3179 on platelet aggregation induced by human atheromatous plaque material. We were able to demonstrate, that EXP3179 inhibits thrombus formation after stimulation with human plaque material. To evaluate the effect of EXP3179 on platelet adhesion and aggregation in vivo we used an established mouse model of carotid injury. In this regard, we -and others -reported that murine thrombus formation in this model crucially depends on GPVI-receptor activation. 3, 7 Here, we show, that EXP3179 substantially reduces platelet adhesion in response to vessel injury underlining the impact on GPVI-receptor-mediated platelet activation by EXP3179 also in vivo.
Study limitations and Clinical Perspectives
Before the onset of the study presented, the pharmacokinetics and -dynamics of EXP3179 in vivo had only been investigated once and in context of a single orallyapplied dose of LOS. 11 Thus, we are the first to consider and apply EXP3179 as an individual potential drug. Although we did not observe any signs of acute intoxication or obvious signs of un-specificity (compared to solvent) when using EXP3179 in micromolar concentrations, further studies will be needed to establish a dosedependent pharmaco-toxicological profile of EXP3179. 13 To summarize, this study describes EXP3179 as a potent inhibitor of collagen-dependent platelet activation, aggregation and adhesion via GPVI in vitro and in vivo. These results indicate EXP3179 as an individual platelet-inhibitory and potentially vasoprotective agent in the experimental attempt to identify new therapeutic strategies to prevent fatal atherothrombotic cardiovascular events. ) over collagen-I coated cover slides. EXP3179 significantly inhibited platelet adhesion on collagen-I under shear conditions. Data are given as relative platelet adhesion in %. Data are mean SD; *p<0.01 vs solvent; n=5 Figure 2 : Impact of EXP3179, LOS and EXP3174 on GPVI-receptor-dependent human platelet aggregation and activation A: Incubation of PRP with EXP3179, LOS, EXP3174 or appropriate solvent was followed by stimulation with 4C9, a GPVI-receptor-activating antibody. EXP3179 and LOS dose-dependently inhibited GPVI-dependent human platelet aggregation analysed by optical aggregometry. The maximum effect was observed at a concentration of 500 μM after stimulation of PRP with 0.1 μg/mL 4c9. EXP3174 did not affect this parameter. Data are given as maximal aggregation in %. Data are mean SD; *p<0.01 vs PRP; #p<0.05 vs PRP; n=5-8 B: Incubation of human PRP with EXP3179, LOS or appropriate solvent followed by stimulation with 4C9 led to a reduction of platelet PAC-1 expression as analysed by flow cytometry. The maximum effect was observed at a concentration of 500 μM after stimulation of PRP with 0.1μg/mL 4c9. EXP3174 did not have a significant impact on GPVI-dependent PAC-1 expression. Specific antibody binding was expressed as mean intensity of immunfluorescence. Data are mean SD; *p<0.01 vs stimulated (stim) PRP; n=3-7 Figure 3 : Impact of EXP3179, LOS and EXP3174 on GPVI-receptor-dependent cell adhesion under shear conditions. CHO-GPVI or CHO-F cells were incubated with EXP3179, LOS, EXP3174 or appropriate solvent followed by perfusion (1000sec -1 ) over collagen-I or BSA coated cover slides. Incubation of CHO-GPVI cells with EXP3179 and LOS led to a reduction of cell adhesion on collagen-I matrices under shear conditions. EXP3174 did not influence this parameter. Data are mean SD; *p<0.01 vs CHO-GPVI adhesion on BSA/glass; **p<0.01 vs CHO-GPVI adhesion on collagen-I; #p<0.05 vs CHO-GPVI adhesion on collagen-I; n=3-7 Figure 5B
Introduction
Ischemic injury of the brain leads to versatile pathological and defensive processes such as neuronal death, inflammation and activation of microglia as well as astrocytes. Due to their multiple protective features, for instance synthesis of neuroprotective factors such as erythropoietin (1) or vascular endothelial growth factor (2) and maintenance of the extracellular glutamate concentration (3), astrocytes may determine the extent of neuronal damage under hypoxic/ischemic injury. Despite numerous studies demonstrating the critical role of astrocytic apoptosis in the pathogenesis of acute and chronic disorders, such as cerebral ischemia or Alzheimer`s disease (4, 5) , the mechanisms regulating astrocytic survival and their capacity to counteract pathological situations are not well understood.
There is increasing evidence for the involvement of the local angiotensin receptor system (ARS) in development, survival and regeneration of neurons. Angiotensin II (ATII) promotes their differentiation and survival in vitro via its receptor subtype 2 (AT2-R) (6) and attenuates hypoxia-induced apoptosis in primary cortical neuronal cultures (7). However, little is known about the role of the ARS in the survival of astrocytes upon different kinds of brain injury. Astrocytes produce ATII and both types of its receptors (AT1-R and AT2-R) (8) . ATII promotes the proliferation of different cell types including astrocytes (9, 10) , and is upregulated together with its AT2-R after ischemic brain injury (11) . The data concerning the effects of ATII during ischemic damage are contradictory: Whilst exogenous application of ATII or AT2-R stimulation decreases the mortality rate in gerbils with unilateral carotid ligation (12, 13) and the long term blockade of AT1-R in rat brain improves the neurological outcome and reduces the infarct volume after experimental ischemia (14) , ATII also mediates programmed cell death through AT2-R in different cell types (15) . So far, the mechanisms of ATII action on the different CNS cell types and the involvement of its receptor subtypes in protective and pathophysioligical mechanisms during hypoxia-associated injury of the brain are still poorly understood.
Selective AT1-R blockade by losartan and other AT1-R antagonists is widely used in treatment of hypertension, a key factor in the pathophysiology of stroke. Although losartan itself is a potent AT1-R antagonist, its antihypertensive action appears to be primarily due to its active metabolite EXP3174 (16) . Polidori et al. (17) have shown a delayed effect of intraperitoneally delivered losartan on central targets of angiotensin action, such as water intake, and that the peripheral administration of EXP3174 inhibited water drinking with higher potency than losartan itself. AT1-R blockade was shown to improve the brain microcirculation and therefore to decrease the vulnerability to brain ischemia and stroke in chronically hypertensive rats (18) . It suppresses the inflammation of brain vessels in spontaneously hypertensive rats (19) and prevents stress-induced gastric ulcers, in part by reducing inflammation in the gastric mucosa (20) , suggesting the involvement of AT1-R in inflammation connected to different kinds of disorders such as ischemia or stress. Inflammation occurs in early stages of acute and chronic neurodegenerative disorders such as stroke or Parkinson's and Alzheimer's disease (21, 22) . A self-amplifying cycle involving brain immune cells (microglia and astrocytes) has been discussed as one of the mechanisms of these inflammation processes. Several attempts have been made to investigate the role of the local angiotensin receptor system in survival of neurons upon different kinds of injury: While losartan is known to increase the protection of neurons provided by ATII against hypoxia-and rotenone-induced cell death (7, 23) , the possible cytoprotective and anti-inflammatory effect of AT1-R antagonists on astrocytes remained unexplored prior to this study. Here, the influence of losartan and its main active metabolite, EXP3174, on hypoxia-induced damage to astrocytes and on their inflammatory response to hypoxic injury has been investigated.
Experimental Procedure
Cell culture
Astroglial primary cultures (APC) were prepared from the brains of newborn Wistar rats as described elsewhere (24) . For the cell viability assay, the cells were grown in 96-well microplates (20000 cells/well), whereas for the multiplex assay of interleukins, 1x10 6 cells were grown in petri dishes (60 mm in diameter). The cells were cultured in Dulbecco's modified Eagle's medium containing 10% foetal calf serum, 100 g/ml streptomycin sulphate and 100 units/ml penicillin at 37°C in an incubator containing an atmosphere of 10%CO 2 in air until day 8 in vitro (DIV, day in vitro). On DIV 8 the medium was removed and fresh medium containing different supplements was added. The samples were assayed as described below.
Synthesis of EXP3174 via EXP3179
EXP3179 was synthesized by previously reported methods (25, 26) and oxidized further to EXP3174 by activated manganese dioxide in H 2 O under reflux for 78 hrs. Excess of MnO 2 was filtered, the solvent was removed in vacuo and the residue (EXP3174, 200 mg, yield 56 %) was purified by acid/base workup (27) .
Incubation with Losartan, EXP3174 and ATII under normoxic and hypoxic conditions
8 day-old cultures were treated for 48 h either with two different concentrations of losartan (100nM or 1 M) kindly provided by MSD SHARP&DOHME (Haar, Germany) or EXP3174 (100nM, 1 M) alone and in combination with 100nM ATII (Sigma, Deisenhofen, Germany). Losartan and ATII were dissolved in phosphatebuffered saline (PBS), EXP3174 was dissolved in DMSO and further diluted with PBS (0.029% final concentration of DMSO). It was previously shown that the viability of astroglial primary cultures is not affected by this DMSO concentration (28) . Cells were cultured for 48h at 37°C either under NC with 10% CO 2 in air or under hypoxic conditions (HC) with 1% O 2 , 10% CO 2 and 89% N 2.
Cell viability assay
Cell death induced by culture conditions and hypoxia was measured in terms of LDH activity in supernatants of cells grown in 96-well microplates. The experiments were performed following the protocol accompanying the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, USA). Briefly, 50 l of standards or 50 l of culture supernatant (controls and treated cells) and 50 l of substrate mix were transferred into a 96-well-plate and incubated for 30 minutes at room temperature. The enzymatic conversion of tetrazolium salt into red formazan product was stopped by 50 l stop solution. Plates were read out with a SUNRISE Elisa-plate Reader (Tecan, Crailsheim, Germany) at 490 nm. LDH released from the cells was expressed as a percentage of total cellular LDH, which was measured after lysis of the cells by addition of Triton X-100 to a final concentration of 0,1% in each well.
Multiplex analysis of cytokines.
At DIV 8 the medium was removed from cells grown in petri dishes and fresh medium containing either 1 M losartan, 1 M EXP3174 or 1 M EXP3174 and 100nM ATII was added. The cells were then further incubated for 48h under NC or HC. Subsequently, 50 l from each dishe used for detection of interleukin-4 (IL-4), IL-5, granulocyte-monocyte-colony-stimulating factor (GM-CSF), interferon-gamma (IFN ) and tumor necrosis factor-alpha (TNF ). The quantification of these cytokines was performed with a Beadlyte® Rat Multi-Cytokine Beadmaster TM Kit (Upstate, Lake Placid, NY) and a Luminex-100 system (Luminex Corporation, Austin, TX) according to the manufacturer's instructions. The cytokine concentrations in cell culture supernatants were extrapolated from their respective standard curves by 5-parameter logistic analysis (29) .
Statistical analyses
Data presented as mean ± SEM (n=6) were normalized to the mean of corresponding controls (normoxic and hypoxic controls) and converted to percentage of control. P <0.05 was considered as significant (* p<0.05; ** p<0,01 , *** p<0,001). To compare the treated samples with controls, one way ANOVA with Dunett's post comparison test was used.
Results
LDH release as a measure for cell damage was investigated under NC and HC in APC incubated with ATII, Losartan, and EXP3174. Under NC, the application of 100nM and 1 M losartan reduced the release of LDH in a concentration-dependent manner: application of 1 M losartan appeared to be more effective than 100nM losartan (Fig. 1A 100nM L, 1 M L vs. N) . The administration of 100nM EXP3174 reduced LDH by 35±11% (Fig. 1A, 100nM EXP) , whereas the application of 1 M EXP3174 resulted in a 52±16% decrease of released LDH (Fig. 1A, 1 M EXP) . Simultaneous administration of 100nM ATII and 1 M EXP3174 brought no additional decrease of LDH-release (63±14%, Fig 1A, AT+EXP) when compared with the effect of 1 M EXP3174 applied alone (52±16%, Fig. 1A, 1 M EXP) . Under HC, 100nM of either EXP3174 or losartan had no effect on release of LDH (Fig. 1B, 100nM L and 100nM EXP) when compared with the hypoxic control (Fig.  1B, H) . The reduction in LDH release after application of 1 M losartan (37±19 %, The concentrations of the inflammatory cytokines IL-4, IL-5, GM-CSF and IFN in the cell culture supernatants were far below the detection range (< 14 pg/ml) under both NC and HC. Only TNF was measurable under NC and 3,5-fold up-regulated upon exposure of the cells to hypoxia (cf. N in Fig. 2A with H in B) . The effect of 1 M losartan on TNF -release under NC (33±10%; Fig. 2A, N+L) was slightly lower than that of 1 M EXP3174 (41±15%; Fig.2A : N+EXP vs. N) in comparison to the normoxic control (N in Fig. 2 A) . The effect achieved by simultaneous application of 100nM ATII and 1 M EXP3174 or losartan (N+AT+EXP and N+AT+L in Fig. 2 A) on TNF -release was similar to the one observed on samples incubated with EXP3174 or losartan alone ( Fig. 2A: 63±13% in N+AT+L vs. 33±10% in N+L and 45±10% in N+AT+EXP vs. 41±15% in N+EXP). Under HC, losartan and EXP3174 showed approximately equal efficacies in preventing TNF release: 1 M losartan or EXP3174 decreased TNF concentration by 40±15% or 34±20%, respectively (Fig.2 B , H+L vs. H+EXP) when compared to the hypoxic control ( Fig. 2 B, H) . Combined application of ATII (100nM) and losartan appeared to decrease TNF (70±15%, H+AT+L in Fig. 2B ) similar to that of ATII with EXP3174 (57±20%, H+AT+EXP in Fig. 2B ).
Discussion
Taking into consideration that the AT1-R antagonist losartan is a pharmacologically well characterized therapeutic agent, this study investigated whether this compound and its main active metabolite, EXP3174, may provide a protection of astrocytes against hypoxia-induced cell damage and prevent them from initiating an inflammatory cascade. The data obtained on cell death in terms of LDH release from astroglial cells show that under both NC and HC, losartan and EXP3174 possess a similar protective potency. Astrocytes are known to express all known angiotensin receptor subtypes, namely AT1-R, AT2-R and AT(1-7)-R (30, 31) . Their increased survival under losartan and its metabolite may be due to 1) the direct antagonistic effect of losartan and EXP3174 on AT1-R or 2) increased availability of endogenously produced (or exogenously applied) ATII for signal transduction via the remaining receptor subtypes. ATII is known to be produced by astrocytes and to be upregulated under ischemic injury of the brain (11) .
Culture condition induces the reactive state of astrocytes, which differs from the resting inactive state typical for these cells in normal brain tissue. This cultureinduced activation of astrocytes is entailed by accelerated differentiation and therefore presumably accelerated cell death. It was previously shown that basal release of LDH under normoxic conditions in astroglial cultures is in a range up to 10% of its total intracellular content (32) . Results presented here show up to 2,8% LDH release by astroglia under normoxic conditions. Even such a low basal amount of LDH under normoxic conditions in cell culture supernatant was significantly reduced by losartan and EXP3174. Cell culture condition used in this study is the mostly used method over last 20 years for cultivation of astroglial cells. The fact that both compounds (losartan and EXP3174) can increase the viability of cells under well established normoxic culture conditions hint at the possible use of AT1-R blockade as a cell culture supplement capable of creating more physiologic conditions for astroglial cells in vitro. Hypoxia resulted in 30% increase of LDH release. The improvement of astroglial survival under hypoxia after application of losartan or EXP3174 shown here is reconcilable with data demonstrating AT1-Rmediated cell death in myocytes, endothelial cells and blood vessels, in vitro as well as in vivo (33, 34, 35) . In contrast to normoxic condition the higher amount of losartan and EXP3174 was needed under hypoxic conditions to improve the survival of astroglial cells: administration of 100nM losartan or EXP3174 revealed no effect on cell survival upon hypoxia. Apparently, AT1-R blockade exerts a direct protective effect on astrocytes during hypoxic injury. Since application of ATII together with EXP3174 was not more efficient in protecting astrocytes from hypoxic cell death than EXP3174 alone, the blockade of AT1-R appears to be more important for survival than the stimulation of AT2-R or A(1-7)-R.
Whether astrocytes can contribute to the local increase of inflammatory factors in response to hypoxia was investigated by multiplex analysis of anti-inflammatory IL-4, IL-5 and GM-CSF, as well as pro-inflammatory IFN and TNF . All these factors have been shown previously to be up-regulated after ischemic injury of the brain (36, 37, 38) . IL-4, IL-5, GM-CSF, IFN were not detectable under NC or HC. It was previously shown that the exogenous application of IFN induces the death of astrocytes via activation of the Jak2/Stat1 pathway in vitro (39) . The results presented here show that even under protracted HC (48h), astrocytes do not respond with measurable changes in their production of IFN . The fact that IL-4 release from astrocytes was not influenced by hypoxia is in concordance with the data reported by Park et al. (40) showing that after lipopolysaccharide-induced inflammation of the brain, IL-4 was expressed exclusively in microglia, but not in astrocytes or neurons. Vitcovic et al. (41) have shown that the expression of GM-CSF in astrocytes was not substantially altered by IL-1, an important activator of reactive astrocytosis that is upregulated in astrocytes after hypoxic injury (42) . The level of IL-5, an antiinflammatory cytokine serving as a mitogenic factor for microglia (43) but not for astrocytes (44) , was not increased under HC either. The absence of antiinflammatory IL-4 and 5, as well as pro-inflammatory IFN in cell culture supernatants after 48h of hypoxia might hint at a marginal role of these cytokines in the immediate inflammatory response of astrocytes to hypoxia. This suggestion is in agreement with data showing a slight transient increase of IL-4 and IL-5 in microglia and inflammatory leucocytes but not astrocytes during experimental allergic encephalomyelitis (45) .
The measured increase in the concentration of TNF in the cell culture supernatants under HC suggests that the immediate inflammatory response of astrocytes to hypoxia might be reflected by release of this potent pro-inflammatory cytokine. The application of losartan and EXP3174 decreased the amount of released TNF under NC and HC. This effect was pronounced by concomitant administration of ATII. Therefore, different AT receptors may be involved in the maintenance of the inflammatory response of astrocytes. Presumably, the production of TNF can be diminished by antagonists at AT1-R and/or stimulation of the other AT receptor subtypes.
The results presented here are somewhat analogous to recently reported data showing the peripheral anti-inflammatory action of the AT1-R antagonist, candesartan, during gastric ulceration (20) to be, in part, reflected by a decreased expression of TNF in stomach sections of rats under cold-restraint stress.
AT1-R activation stimulates a multitude of signalling pathways including the nuclear factor-kappaB (NF-B) pathway. In astrocytes the induction of this signal effector leads to early up-regulation and subsequent release of TNF . The inhibition of the NF-B transduction pathway was shown to reduce the secretion of TNF from astrocytes (46). It can be therefore suggested that decrease of TNF release from astroglia provided by losartan or EXP3174 originates most likely from their activation-reducing effect on NF-B.
A comparison of the anti-inflammatory effects achieved by losartan and EXP3174 reveals nearly equal efficacy of both compounds under NC and HC, suggesting that losartan delivered to the brain might reduce the susceptibility of astrocytes to hypoxic injury and provide an anti-inflammatory effect even without being converted to EXP3174 in the liver.
In summary, it can be concluded that AT1-R blockade could be of therapeutic benefit during neurodegenerative disorders accompanied by inflammation, such as Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis due to its anti-inflammatory and vulnerability-reducing effect on astrocytes. Fig 1 A) and its simultaneous application with 100nM ATII led to a significant LDHdecrease (AT +1 M EXP in Fig.1A ). Under HC (Fig.1B) both, losartan and EXP3174 applied in concentration of 100nM brought no changes in released LDH amount. 1 M losartan or EXP3174 and 100nM AT together with EXP3174 significantly reduced hypoxiainduced cytotoxicity (cf. 1 M L, 1 M EXP and AT+1 M EXP with control H in Fig.1B) . HC (B) . The quantification of TNF revealed a 3,5-fold increase in TNF -concentration in cell cultures exposed to hypoxia (cf. N in Fig.2A with H in Fig.2B ). Under NC ( Fig. 2A) losartan and EXP3174 decreased the TNF -release with an equal potency, whereas under HC the effect of EXP3174 on TNFrelease was considered as insignificant due to a high variability of the data within the treated group (Fig.2B H+EXP) . Simultaneous application of ATII with EXP3174 or losartan enhanced the significance of TNF -reducing effect in NC (Fig.2A, N+AT+L and N+AT+EXP) and HC (Fig. 2B, H+AT+L and H+AT+EXP) .
